



Original article

Impact of Preoperative Platelet Count on Perioperative Outcome After Laparoscopic Splenectomy for Idiopathic Thrombocytopenic Purpura[☆]



Belen Martin Arnau,* Víctor Turrado Rodriguez, Ernesto Tartaglia, Jesús Bollo Rodriguez, Eduardo M. Targarona, Manuel Trias Folch

Servicio de Cirugía General y Aparato Digestivo, Hospital Santa Creu i Sant Pau, Universidad Autónoma de Barcelona, Barcelona, Spain

ARTICLE INFO

Article history:

Received 5 March 2016

Accepted 5 May 2016

Available online 3 September 2016

Keywords:

Laparoscopic splenectomy

Idiopathic thrombocytopenic

purpura

Severe thrombocytopenia

ABSTRACT

Introduction: Laparoscopic splenectomy (LS) is the preferred treatment of idiopathic thrombocytopenic purpura (ITP) when medical treatment fails. The objective was to evaluate the feasibility and safety of LS according to the preoperative platelet count.

Methods: This study is a retrospective analysis of a series of 199 patients who underwent LS for ITP from 1993 to 2015. The patients were divided into 3 groups according to platelet count: group I ($<10 \times 10^9/L$), group II ($10-50 \times 10^9/L$) and group III ($>50 \times 10^9/L$).

Results: Operative time was significantly lower in Group III compared to Group I and II (100 ± 53 and 105 ± 61 min, $P < .025$). Intraoperative blood loss was statistically higher in group I (263 ± 551 ml) with respect to the other 2: group II (128 ± 352 ml) and group III (24 ± 62 ml) ($P < .003$). Hospital stay was 6.4 ± 5.8 days in group I, significantly higher compared to groups II and III (3.8 ± 2.3 and 3.2 ± 1.8 days, respectively ($P < .003$)).

Conclusion: Conducting a LS in ITP patients with low platelet counts is effective and safe.

Published by Elsevier España, S.L.U. on behalf of AEC.

Impacto del recuento plaquetario preoperatorio en la evolución perioperatoria tras la esplenectomía laparoscópica por púrpura trombocitopénica idiopática

RESUMEN

Palabras clave:

Esplenectomía laparoscópica

Púrpura trombocitopénica

idiopática

Trombocitopenia severa

Introducción: La esplenectomía laparoscópica (EL) es el tratamiento de elección de la púrpura trombocitopénica idiopática (PTI) cuando fracasa el tratamiento médico. El objetivo de este estudio ha sido evaluar la factibilidad y seguridad de la EL según el recuento preoperatorio de plaquetas.

* Please cite this article as: Martin Arnau B, Turrado Rodriguez V, Tartaglia E, Bollo Rodriguez J, Targarona EM, Trias Folch M. Impacto del recuento plaquetario preoperatorio en la evolución perioperatoria tras la esplenectomía laparoscópica por púrpura trombocitopénica idiopática. Cir Esp. 2016;94:399-403.

[☆] Corresponding author.

E-mail addresses: belen_marar@hotmail.com, amartinar@santpau.cat (B. Martin Arnau).

Métodos: Análisis retrospectivo de una serie de 199 pacientes a los que se les realizó una EL por PTI durante el periodo 1993-2015. Los pacientes se dividieron en 3 grupos según las cifras de plaquetas: grupo I ($<10 \times 10^9/L$), grupo II ($10-50 \times 10^9/L$) y grupo III ($>50 \times 10^9/L$).

Resultados: El tiempo operatorio fue significativamente menor en el grupo III respecto a los grupos I y II (100 ± 53 y 105 ± 61 min; $p < 0,025$). La pérdida hemática intraoperatoria fue estadísticamente superior en el grupo I (263 ± 551 ml) respecto a los otros 2: grupo II (128 ± 352 ml) y grupo III (24 ± 62 ml) ($p < 0,003$). La estancia hospitalaria de $6,4 \pm 5,8$ días en el grupo I fue significativamente superior a la de los grupos II y III ($3,8 \pm 2,3$ y $3,2 \pm 1,8$ días, respectivamente; $p < 0,003$).

Conclusiones: La realización de una EL en pacientes con PTI con recuentos bajos es efectiva y segura.

Publicado por Elsevier España, S.L.U. en nombre de AEC.

Introduction

The laparoscopic approach has become the technique of choice in hematologic diseases requiring splenectomy, and it is most frequently indicated for the treatment of idiopathic thrombocytopenic purpura (ITP). In these patients, the first lines of treatment are corticosteroid therapy and, more recently, anti-receptor treatment.¹⁻⁴ Splenectomy is only indicated when medical treatment fails.

ITP is an autoimmune disease characterized by the destruction of platelets in the spleen, resulting in decreased peripheral levels, and it is associated with hemorrhagic clinical manifestations. Usually, platelet levels are optimized prior to surgery using corticosteroids or hyperimmune gammaglobulin. Intraoperative platelet transfusion is avoided due to the rapid destruction and because transfusion is not free of risks.⁵ However, it is not always possible to achieve normalized preoperative counts, and laparoscopic splenectomy (LS) sometimes needs to be done with very low platelet counts, even at levels below 30×10^9 .⁹

The objective of this study was to evaluate perioperative evolution after LS in patients affected by ITP according to preoperative platelet counts.

Methods

We analyzed patients who underwent LS for ITP and were registered in the prospective laparoscopic splenic surgery database compiled by the Surgery Department at the Hospital de Santa Creu y Sant Pau in Spain. Out of the 435 patients who had LS between 1993 and 2015, in 199 (67 males and 132 females) LS was used to treat ITP. Splenectomy was indicated

in cases of thrombocytopenia associated with hemorrhagic manifestations in patients resistant to conservative treatment with steroids or immunoglobulin. The LS technique has been previously described in the literature.¹⁵

There is no consensus about the lower limit of safety of platelet counts for conducting laparoscopic procedures, although levels are usually between 30 and $50 \times 10^9/L$. Patients were divided empirically into 3 groups according to their preoperative platelet counts: group I, low, $n=19$ ($<10 \times 10^9/L$); group II, intermediate, $n=80$ ($10-50 \times 10^9/L$) and group III, high, $n=100$ ($>50 \times 10^9/L$).

We collected demographic data (age and sex), analytical data (hemoglobin and platelet count), preoperative treatment used for increasing platelet count (hyperimmune immunoglobulin, corticosteroids), operative time, intraoperative blood loss, conversion to open surgery, transfusion of erythrocytes or platelets, postoperative morbidity according to the Clavien-Dindo⁸ classification and hospital stay.

Statistical Analysis

SPSS version 16 statistical software was used. The differences between the variables of the 3 groups were compared by ANOVA, Kruskall-Wallis and Mann-Whitney tests, as necessary. A $P < .05$ was considered statistically significant, and means and standard deviation were used to represent the results.

Results

In the cohort of 199 patients, 68% were women and 31% men. Mean age was 43 ± 18 years (Table 1). The 3 groups were similar from a demographic standpoint and the mean preoperative platelet count was $69 \times 10^9/L$.

Table 1 – Demographic Characteristics.

Variables	Group I, n=19 ($<10 \times 10^9/L$)	Group II, n=80 ($10-50 \times 10^9/L$)	Group III, n=100 ($>50 \times 10^9/L$)	P
Sex, male/female (%)	45/55	24/59	28/64	.368
Age (SD)	51 ± 21	44 ± 17	41 ± 19	.078
BMI (SD)	26 ± 3	26 ± 5	26 ± 5	.886
Platelet count ($10^9/L$)	5.50 ± 4.5	32.2 ± 8.1	129 ± 76	

SD: standard deviation.

Mean. ANOVA value of P.

Table 2 – Intraoperative and Postoperative Complications.

Complications (Clavien-Dindo)	Group I, n:19 (<10×10 ⁹ /L)	Group II, n: 80 (10–50×10 ⁹ /L)	Group III, n: 100 (>50×10 ⁹ /L)
1. Hemoperitoneum	2 (IIb)	5 (IIIb)	5 (IIIb)
2. Wall hematoma	0	2 (II)	3 (II)
3. Subphrenic hematoma	0	1 (I)	1 (II)
4. Subphrenic abscess	0	3 (IIIa)	0
5. Pancreatic fistula	0	0	1 (IIIb)
6. Portal thrombosis	0	1 (IIIa)	0
7. Gastrointestinal hemorrhage	1 (IIIa)	0	0
8. Total complications n/No. (%)	3/19 (15)	12/80 (14)	10/100 (10) P=.812

A total of 31 patients required an attempt at platelet count optimization by administering intravenous hyperimmune immunoglobulin (1 g/kg, single dose) 24–48 h before surgery.

The operative time of group III (90 ± 35 min) was significantly shorter ($P=.025$) than that of the other 2 groups (group I: 100 ± 53 min and group II: 105 ± 61 min).

Intraoperative blood loss in group I was 263 ± 551 mL, which was significantly higher than that of groups II (128 ± 352 mL) and III (24 ± 62 mL) ($P<.003$).

Hospital stay was longer in group I (6.4 ± 5.8 days) compared to other groups (group II: 3.8 ± 2.3 days; group III: 3.9 ± 1.9 days; $P<.003$). Group I patients had ASA classifications higher than those in group II (10.5 vs 3.7% ASA III; $P=.23$).

No significant differences were observed between the 3 groups in terms of the need for conversion to open surgery, postoperative complications (Table 2) or postoperative increase in platelet count (Fig. 1).

Discussion

The first line of treatment of ITP is corticosteroid therapy, and in recent years medical options have been added (thrombopoietin agonist, rituximab) to avoid the secondary effects of steroids or to avoid/postpone splenectomy. Nonetheless, splenectomy continues to be the second line of treatment in

patients who do not respond to medical treatment.^{9,10} The British Committee for Standards in Haematology (BCSH) recommends splenectomy in patients with platelet counts of $30 \times 10^9/L$ that do not increase after medical treatment.¹¹ Currently, LS in patients with ITP is a safe, effective technique,^{3–6} even though it was traditionally thought that severe coagulation alterations or platelet counts below $50 \times 10^9/L$ were absolute contraindications for laparoscopic treatment. Therefore, a priority objective in the preoperative preparation of patients is the optimization of the platelet count using corticosteroids or immunoglobulin, although, in some cases, the patient's clinical condition or response to medical treatment do not allow for normalization.

In this study, we have observed that platelet counts under $50 \times 10^9/L$, and even as low as $10 \times 10^9/L$ (which is a level far below the limit that, to date, had been considered empirically safe, as also reported by other authors), do not impede performing a safe LS. At the same time, LS carried out at platelet counts between 10 and $50 \times 10^9/L$ was no different than conducting LS at counts greater than $50 \times 10^9/L$ in terms of blood loss, operative time or postoperative complications. However, platelet counts lower than $10 \times 10^9/L$ had an important impact on perioperative outcome, with significantly greater intraoperative blood loss, longer operative time and prolonged hospital stay (Table 3).

Other authors have also evaluated the impact of platelet count on perioperative patient progress after LS (Table 4). Vecchio et al.¹² and Keidar et al.^{5,6,13} concluded that LS is a safe procedure in high-risk patients, with platelet counts $>20 \times 10^9/L$, in whom they observed low morbidity and need for conversion to open surgery. Likewise, in patients with counts lower than $10 \times 10^9/L$, Chen and Zhong^{7,14,15} reported that LS does not cause significant bleeding compared to our results, in which the patients with lower platelet counts presented greater blood loss, with the need for blood transfusion, and longer operative time compared to the other 2 groups with higher platelet counts. As for the correlation between conversion rate and low platelet count, in our series we have found no significant relationship. This finding is similar to other authors, like Keidar,⁶ who also reported that platelet count did not affect conversion. However, as in our series, the Keidar series had a small number of patients in this group; therefore, it is possible that low platelet count could play a role in conversion.

Another aspect mentioned by some authors is the use of drains. In a recent publication by Yunquiang of patient groups with very low platelet counts (like group I in our series, $<10 \times 10^9/L$), drainage is a useful postoperative method to




Fig. 1 – Evolution of pre- and post-operative platelet count; P=.602.

Table 3 – Variables Studied.

	Group I n=19 (<10×10 ⁹ /L)	Group II n=80 (10–50×10 ⁹ /L)	Group III n=100 (>50×10 ⁹ /L)	P
Blood loss (mL)	263±550.7	128±352.3	24±61.7	.003
Operative time (min)	100±53.2	105±60.9	90±35.2	.025
Hospital stay (days)	6.37±5.83	3.79±2.29	3.88±1.88	.003
Mean. ANOVA value of P.				

Table 4 – Laparoscopic Splenectomy With Low Platelet Count: Review of the Literature.

Studies	n	Platelet count (×10 ⁹ /L)	Operative time (min)	Blood loss (mL)	Complications, n (%)	Conversion, n (%)
Chen ⁷	30	<10	170	65	2 (6.6)	5 (6.6)
Zhong ^{13,14}	10	<10	157	44	0	0
Targarona ¹⁶	19	<10	115	263	3 (16)	2 (10)
Vechhio ¹²	20	<20	n/r	45	0	0
Keidar ^{6,13}	12	<20	80	n/r	3 (25)	0
Zhong ^{13,14}	30	<20	200	170.5	0	2 (6.6)

n/r: not recorded.

detect bleeding, so drain catheters are placed in all their patients.¹⁷

Currently, when LS is performed, the surgeon has resources and surgical tools that minimize the risk of bleeding: (1) the position of the patient in lateral decubitus, which medializes the spleen, thereby making its mobilization and dissection easier; (2) early ligation of the splenic artery, which reduces intrasplenic platelet destruction and favors self-transfusion; and (3) the use of instruments for vascular sealing and dissection, as well as articulated endostaplers to simplify the division of the splenic hilum and achieve better vascular control and less bleeding. The previously mentioned authors also concur on these aspects.¹⁶

To conclude, our opinion is that LS in ITP patients can be done with any platelet count in a safe manner, even at levels lower than 10×10⁹/L. Nevertheless, low platelet counts can have an important clinical impact, with increased blood loss, operative time and hospital stay.

Authorship/Collaborators

The following authors have contributed to the composition of the article, critical review and approval of the final version: B. Martin, E. Targarona, J. Bollo and M. Trias.

These authors have contributed to the study design, data acquisition and collection, analysis and interpretation of the results: B. Martin, E. Tartaglia and V. Turrado.

Conflict of Interests

The authors have no conflict of interests to declare.

REFERENCES

- Delaitre B, Maignien B. Splenectomy by laparoscopic approach: report of a case. *Presse Med*. 1991;20:2263.
- Casaccia M, Torelli P, Pasa A, Sormani MP, Rossi EM, the IRSS Centers. Putative predictive parameters for the outcome of laparoscopic splenectomy: multicenter analysis performed on the Italian registry of laparoscopic surgery of the spleen. *Ann Surg*. 2010;251:287–91.
- Friedman RL, Fallas MJ, Carroll BJ. Laparoscopic splenectomy for ITP. The gold standard. *Surg Endosc*. 1996;10:991–5.
- Trias M, Targagna EM, Espert JJ. Impact of hematological diagnosis on early and late outcome after laparoscopic splenectomy: an analysis of 111 cases. *Surg Endosc*. 2000;14:556–60.
- Szold A, Kais H, Keidar A, Nadav L, Eldor A, Klausner JM. Chronic idiopathic thrombocytopenic purpura (ITP) is a surgical disease. *Surg Endosc*. 2002;16:155–8.
- Keidar A, Feldman M, Szold A. Analysis of outcome of laparoscopic splenectomy for idiopathic thrombocytopenic purpura by platelet count. *Am J Hematol*. 2005;80:95–100.
- Chen X, Peng B, Cai Y, Zhong J, Wang Y, Wu Z, et al. Laparoscopic splenectomy for patients with immune thrombocytopenia and very low platelet count: is platelet transfusion necessary? *J Surg Res*. 2011;170:225–32.
- Dindo D, Dermartines N, Clavien PA. Classification of surgical complications. A new proposal with evaluation in a cohort of 63336 patients and results of a survey. *Ann Surg*. 2004;240:205–13.
- Stasi R, Newland A, Thornton P, Pabinger I. Should medical treatment options be exhausted before splenectomy is performed in adult ITP patients? A debate. *Ann Hematol*. 2010;89:1185–95.
- Provan D, Stasi R, Newland AC, Blanchette VS, Bolton-Maggs P, Ian Greer JB, et al. International consensus report on the investigation and management of primary immune thrombocytopenia. *Blood*. 2010;115:168–86.
- British Committee for Standards in Haematology General Haematology Task Force. Guidelines for the investigation and management of idiopathic thrombocytopenic purpura in adults, children and in pregnancy. *Br J Haematol*. 2003;120:574.
- Vecchio R, Cacciola E, Lipari G, Privitera V, Polino Ch, Cacciola R. Laparoscopic splenectomy reduces the need for platelet transfusion in patients with idiopathic thrombocytopenic purpura. *J Soc Laparosc Surg*. 2005;9:415–8.
- Keidar A, Sagi B, Szold A. Laparoscopic splenectomy for immune thrombocytopenic purpura in patients with severe refractory thrombocytopenia. *Pathophysiol Haemost Thromb*. 2003;33:116–9.

14. Wu Z, Zhong J, Pankaj P, Peng B. Laparoscopic splenectomy for immune thrombocytopenia (ITP) patients with platelet counts lower than $1\ 3\ 10^9/l$. *Int J Hematol.* 2011;94:533–8.
15. Wu Z, Zhong J, Li J, Zhu Y, Peng B. The feasibility of laparoscopic splenectomy for ITP patients without preoperative platelet transfusion. *Hepatogastroenterology.* 2012;59:81–5.
16. Balagué G, Targarona EM, Cerdán G, Novell J, Montero O, Bendahan G, et al. Long-term outcome after laparoscopic splenectomy related to hematologic diagnosis. *Surg Endosc.* 2004;18:1283–7.
17. Cai Y, Liu X, Peng B. Should we routinely transfuse platelet for immune thrombocytopenia patients with platelet count less than $10\times 10^9/l$. Who underwent laparoscopic splenectomy? *WJS.* 2014;38:2267–72.